Comparative Pharmacology
Head-to-head clinical analysis: DIACOMIT versus MYSOLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIACOMIT versus MYSOLINE.
DIACOMIT vs MYSOLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stiripentol is an anticonvulsant that potentiates GABAergic neurotransmission by acting as a positive allosteric modulator of GABA-A receptors and inhibiting GABA transaminase. It also inhibits CYP2C19 and other cytochrome P450 enzymes, thereby increasing plasma concentrations of concomitant antiepileptic drugs like clobazam.
Primidone is a barbiturate anticonvulsant that acts by enhancing GABA-A receptor activity and possibly by blocking sodium channels.
10 mg/kg/day orally in two divided doses; increase weekly by 10 mg/kg/day to 70 mg/kg/day or 3 g/day, whichever is lower.
250 mg orally 3 times daily; may increase by 250 mg/day every 3 days; usual maintenance 250 mg 3-4 times daily; maximum daily dose 1500 mg.
None Documented
None Documented
Terminal elimination half-life: 13-20 hours; in severe renal impairment (CrCl <30 mL/min), half-life prolonged to 40-60 hours. Requires dose adjustment.
Primidone: 5-15 hours (mean 10 hours); PEMA: 10-18 hours; Phenobarbital: 50-120 hours. Steady state achieved in 2-4 weeks due to accumulation of phenobarbital.
Primarily renal excretion: 50% as unchanged drug, 30% as glucuronide conjugate, 20% via fecal/biliary routes.
Primidone is excreted primarily in urine; approximately 60-80% as unchanged drug and metabolites (PEMA, phenobarbital), with less than 10% in feces.
Category C
Category C
Anticonvulsant
Anticonvulsant